Global News

Wood remains highly bullish on SpaceX, calling it a potential “most important company in global history.”

South Korea’s stock markets declined for a second day amid chip losses after SK Hynix Inc.’s second-quarter results failed to meet Wall Street expectations.

Apple, Coca-Cola, and Philip Morris International surged to all-time highs on Tuesday as positive catalysts, strong earnings results, and Wall Street optimism helped the shares higher.

An arbitrator recently dismissed Sellas’ claims against 3D Medicines and ordered about $1 million in legal-cost payments.

Conflict in the Middle East escalated again – the U.S. said that Iranian forces had attacked the American military on Tuesday evening.

BlackRock disclosed ownership of 26.5 million HIMS shares, representing a stake of about 12%.

Tesla’s 14-day RSI fell to 27.34, its lowest since March 2025 and below the typical 30 oversold threshold.

Wall Street is expecting Bloom Energy to post a 106% growth in revenue, while earnings per share are expected to grow more than 4x.

Nio bought about 18.24 million CXMT shares through Nio Power Technology, with the position subject to an 18-month lockup.

Vodafone said 45 satellites are needed to begin U.K. beta testing, now targeted for early 2027, with the U.K. set to be the first launch market.

Robinhood Markets said on Monday that its IPO roadshow for Robinhood Ventures Fund II will be livestreamed on its app and YouTube on Aug. 3.

Sellas estimated cash and cash equivalents of $138.3 million as of June 30.

The Direxion Daily South Korea Bull 3X Shares is declining amid a sharp selloff in chip stocks globally, including in South Korea.

ARK Invest bought 124,543 SpaceX shares worth about $14.1 million and 27,864 Tesla shares worth about $8.6 million.

Paramount Skydance, Uber and Stem fell to fresh annual lows on Monday amid growing regulatory, competitive, and financial concerns.

Wall Street turned more cautious, with Roth, B. Riley and Cantor flagging elevated approval risk.

At least six analysts hiked price targets on Verizon Communications, citing a positive backdrop after its second-quarter earnings results.

Markets are largely focused on pivotal earnings from major hyperscalers this week, including Amazon.com, Apple, Meta and Microsoft.

Morningstar similarly called Starlink a “niche solution, not a telecom disruptor,” with a realistic $129 billion global market.

CEO Angelos Stergiou said recently on “FOX & Friends” that AI and precision medicine could speed drug development and improve patient selection.

According to a new Morningstar research report, Verizon Communications stock has a fair value estimate of $54, implying an upside of more than 23% from its last close.

AT&T stock gained 10.64% last week, outperforming benchmark S&P 500 index by more than 11 percentage points, which is the largest weekly performance in 25 years, as per Barchart.

Outlook expects a U.S. launch before year-end and anticipates 12 years of market exclusivity.

Nio received about 18.24 million CXMT shares, though the stake is subject to an 18-month lockup.

Coinbase co-founder and CEO Brian Armstrong said in a post on X that a pivot from crypto to AI is “the wrong way to think about the world.”

An FDA advisory panel backed six of seven peptides for possible inclusion on the 503A compounding list, with Emideltide the only rejection.

Weekend chatter focused on ImmunityBio’s quiet July, with some bulls calling the silence the “quiet before the kraken.”

SpaceX is expected to report earnings next week, followed by a lockup expiration that could free nearly 1 billion pre-IPO shares for sale.

During an interview on Fox & Friends on Friday, Stergiou said AI will play a major role in helping cure cancer by enabling more precise treatments.

Tesla influencer AleXandra Merz expects a potential Tesla-SpaceX merger to take seven to 12 months to complete.

T-Mobile called satellite service a complement to cellular networks and said it could become “table stakes.”

ASTS recently raised $1.15 billion to support growth and secure launch capacity as it remains heavily reliant on SpaceX.

A new MD Anderson study found that survival was significantly shorter among older and higher-risk AML patients.

Leerink sees a $2.2 billion peptide market, with Hims potentially capturing about 20%.

Musk also said that SpaceX went public partly to let ordinary investors participate, even as its shares head toward a third straight weekly decline.

According to an Axios report, two U.S. officials confirmed that no new orders have been issued to the military.

The motivation behind the latest donations is unclear, adding to the ongoing mystery of why people keep sending Bitcoin to crypto’s richest holders.

Brent crude futures extended gains for a fifth straight session, crossing the triple-digit mark for the first time since May 26, 2026.

Deepwater's Gene Munster said Musk's comments revealed deeper ties, with Tesla and SpaceX collaborating across Starlink, Terafab, Grok and Digital Optimus.

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

Shkreli reiterated his long-standing bearish stance on SLS, although he previously acknowledged making “a bad call” on Capricor after its positive HOPE-3 trial results.

Analyst Gene Munster sees Tesla’s 2027 Capex reaching $25 billion, above Wall Street’s $21 billion estimate.

The offering could help cover the remaining 2% of traffic beyond AT&T’s network.

Philip Morris and Phillips 66 stocks gained following better-than-expected quarterly earnings and upbeat brokerage commentary, respectively.

France has flagged risks related to speeding, driver attention, and performance in complex urban environments.

VinFast targets at least 300,000 global deliveries this year, up from about 200,000 in 2025.

More than 550 million viewers watched on television screens, with the Spain-Argentina final averaging 21 million viewers per minute.

Morgan Stanley believes GeniTech’s standalone debut could help investors view Nio as more than a cash-intensive EV manufacturer.

The new panelists bring expertise in neurology, pain, dermatology, gastroenterology, addiction, cancer pharmacology and patient advocacy.

AST SpaceMobile’s stackable satellite design can support launches of three, five, six or eight BlueBirds on a single mission.